Could this existing drug be a new treatment for dyskinesia?

In 2021, supporters like you helped fund research into NLX-112, a drug that could potentially treat dyskinesia. Newly announced results of the trial offer hope of a potential breakthrough treatment for dyskinesia, as well as other motor symptoms, in years not decades.

A breakthrough for the Parkinson's community

Dyskinesia, involuntary muscle movements, affects over half of the people with Parkinson's taking levodopa within the first 5 years of taking the drug. After 10 years, this rises to 80%. 

What was the trial?

Bio-pharma company, Neurolixis, have just completed the first part of the second phase of a clinical trial looking into whether a drug, NLX-112, can treat dyskinesia caused by levodopa. The trial was co-funded by Parkinson's UK through the Parkinson's Virtual Biotech and the Michael J. Fox Foundation. 

Excitingly, the final results of this phase showed that NLX-112 also improved motor symptoms. This could change the lives of people with Parkinson's.

What happened in the trial? 

The clinical trial tested the drug in people with Parkinson's. The trial was run by world-leading expert Professor Per Svenningsson. Kicking off in 2020, the study recruited 22 participants to take part in an 8 week trial in Sweden. 

15 participants received NLX-112 and 7 received a placebo drug. This was the first time the drug had been tested in people with Parkinson's so the study aimed to test the safety, tolerability and effectiveness of the drug. 

This trial was only possible because of generous donations from supporters like you. Will you help fund the next breakthrough?

I would like to donate the following amount:
  • Paypal accepted
  • Mastercard accepted
  • Visa accepted
  • American Express accepted

We’re delighted about the results of the NLX-112 trial

  • Early results demonstrated that NLX-112 was safe, well tolerated and reduced symptoms of dyskinesia 

  • Further analysis showed that participants had a significant reduction in movement symptoms, such as slowness, tremor and stiffness. 

  • Encouragingly, these improvements were seen with relatively low doses of the drug. This suggests that higher doses and longer treatment could produce even better results. 

Next steps

This was a small scale trial so further studies are needed to prove the effectiveness of the drug. The next stage of the trial would likely look at the potential effectiveness in a larger group, over a longer time. 

There'l be a third phase testing the drug on an even larger scale and if the next studies have positive results, NLX-112 could be available as a new treatment for Parkinson's by 2030. 

Will you help back the next breakthrough? Fund more pioneering research like the NLX-112 trial by making a donation today. 

Animation exploring the clinical trial of NLX-112

The NLX-112 trial from the beginning

Look back on the aims of this trial from when the research started.